Lixte Biotechnology Holdings Stock Analysis

Lixte Stock Analysis Notes

About 20.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 1.73. Lixte Biotechnology last dividend was issued on the 20th of November 2020. The entity had 1:10 split on the 5th of June 2023. Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company was founded in 2005 and is based in Pasadena, California. Lixte Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people. To find out more about Lixte Biotechnology Holdings contact Bastiaan MSc at 631 830 7092 or learn more at https://lixte.com.

Lixte Biotechnology Investment Alerts

Lixte Biotechnology Upcoming and Recent Events

Lixte Biotechnology Environmental, Social, and Governance (ESG) Scores

Lixte Stock Institutional Investors

Note, although Lixte Biotechnology's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Lixte Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.36 M.

Lixte Profitablity

Management Efficiency

Lixte Biotechnology has return on total asset (ROA) of (0.8733) % which means that it has lost $0.8733 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.6333) %, meaning that it created substantial loss on money invested by shareholders. Lixte Biotechnology's management efficiency ratios could be used to measure how well Lixte Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.12 in 2025. Return On Capital Employed is likely to drop to -1.54 in 2025. At this time, Lixte Biotechnology's Liabilities And Stockholders Equity is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 106.3 K in 2025, whereas Total Current Liabilities is likely to drop slightly above 290.7 K in 2025.

Technical Drivers

As of the 22nd of January, Lixte Biotechnology secures the Mean Deviation of 5.54, downside deviation of 6.86, and Risk Adjusted Performance of 0.0801. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Lixte Biotechnology, as well as the relationship between them.

Lixte Biotechnology Price Movement Analysis

Lixte Biotechnology Insider Trading Activities

Lixte Biotechnology Outstanding Bonds

Lixte Biotechnology Predictive Daily Indicators

Lixte Biotechnology Corporate Filings

Lixte Biotechnology Forecast Models

Lixte Biotechnology's time-series forecasting models are one of many Lixte Biotechnology's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Lixte Biotechnology's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Lixte Biotechnology prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Lixte shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Lixte Biotechnology. By using and applying Lixte Stock analysis, traders can create a robust methodology for identifying Lixte entry and exit points for their positions.

When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.